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Abstract
The role of antigen-specific secretory IgA (SIgA) has been studied extensively, whereas there is a limited body of evidence
regarding the contribution of non-specific SIgA to innate immune defenses against invading pathogens. In this study, we
evaluated the effects of non-specific SIgA against infection with Vibrio cholerae O139 strain MO10 and biofilm formation.
Seven day old infant mice deficient in IgA (IgA
-/- mice) displayed significantly greater intestinal MO10 burden at 24 hr post-
challenge when compared to IgA
+/+ pups. Importantly, cross-fostering of IgA
-/- pups with IgA
+/+ nursing dams reversed the
greater susceptibility to MO10 infection, suggesting a role for non-specific SIgA in protection against the infection. Since
biofilm formation is associated with virulence of MO10, we further examined the role of human non-specific SIgA on this
virulence phenotype of the pathogen. Human non-specific SIgA, in a dose-dependent fashion, significantly reduced the
biofilm formation by MO10 without affecting the viability of the bacterium. Such an inhibitory effect was not induced by
human serum IgA, IgG, or IgM, suggesting a role for the oligosaccharide-rich secretory component (SC) of SIgA. This was
supported by the demonstration that SIgA treated with endoglycosidase H, to cleave the high-mannose containing terminal
chitobiose residues, did not induce a reduction in biofilm formation by MO10. Furthermore, the addition of free mannose
per se, across a wide dose range, induced significant reduction in MO10 biofilm formation. Collectively, these results suggest
that mannose containing oligosacchardies within human non-specific secretory IgA can alter important virulence
phenotypes of Vibrio cholerae such as biofilm formation, without affecting viability of the microorganism. Such effects may
contribute significantly to innate immune defenses against invading pathogens in vivo in the gastrointestinal tract.
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Introduction
The large surface area of mucosal membranes is a major portal
of entry and site for colonization by microorganisms [1]. Mucosal
surfaces are protected by fortified host defense mechanisms,
including immunoglobulin A (IgA), the predominant immuno-
globulin in these compartments [2]. The polymeric immunoglob-
ulin receptor (pIgR) is expressed on the basolateral surface of
epithelial cells and transports IgA as well as pentameric IgM from
the lamina propria into mucosal secretions [3]. Upon pIgR-
mediated IgA transcytosis, a portion of the pIgR is cleaved off and
released as the secretory component (SC) bound to dimeric IgA,
forming secretory IgA (SIgA) [4–7].
Secretory IgA has been shown to be involved in the clearance of
immune complexes [8], extracellular neutralization of pathogen
infectivity [9], and intracellular neutralization of bacterial
lipopolysaccharide (LPS) and viruses within epithelial cells [10].
Much of the available evidence regarding the protective role of
SIgA against pathogens is derived from studies of antigen-specific
IgA [11]. However, there is an accumulating body of evidence to
suggest that non-specific SIgA also may assist in mediating
mucosal homeostasis and modulating inflammation at mucosal
surfaces [12]. For example, we [13] have shown that mice deficient
in pIgR displayed significantly enhanced intestinal inflammation
in response to dextran sodium sulfate induced colitis. It is not clear
how non-specific SIgA mediates these effects; however, several
studies [14], including ours [13], point toward an important
contribution of the secretory component (SC). More recent studies
have shown the probable role of glycans on SIgA in mediating the
recognition of bacterial polysaccharides in innate immune
responses [15].
Vibrio cholerae is a Gram negative motile bacterium that is
responsible for the life threatening exhaustive diarrheal disease,
cholera [16]. Epidemics of cholera are observed in southern Asia,
Africa, and South America and are still prevalent as seasonal
outbreaks [16]. V. cholerae persists in the environment by forming
biofilms [17] and in the human host, as suggested by the presence
of biofilm-like bacterial aggregates present in stool samples from
cholera-infected patients[16,18–20]. Removal of such aggregates
from stool-contaminated water has been correlated with significant
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cholera-infected patients also display V. cholerae coated with SIgA,
suggesting an important contribution of IgA in interaction and
elimination of the bacterium [18]. Given (a) the suggested role of
non-specific SIgA in protection against mucosal pathogens, (b) the
evidence of interaction between SIgA and V. cholerae, and (c) the
correlation of biofilm formation with virulence, we evaluated the
effects of SIgA on biofilm formation and virulence of V. cholerae.
In this study, we determined the effect of non-specific SIgA on
the colonization and biofilm formation by O139 strain of V. cholerae
(MO10) [22]. We found that infant suckling mice deficient in IgA
displayed greater intestinal bacterial burdens than wild type pups
following MO10 challenge. This effect could be reversed by
feeding milk from wild type dams, suggesting a role for passively
transferred non-specific SIgA in milk. Non-specific human SIgA,
but not serum IgA or serum IgG and IgM, inhibited biofilm
formation by MO10 in vitro, without affecting viability of the
bacterium. The inhibitory effect on biofilms was reversed by
removal of the high mannose containing oligosaccharides from
SIgA, or could be induced by free mannose, suggesting an
important role for oligosaccharides within SIgA in mediating this
effect.
Results
Non-specific SIgA is involved in reduction of Vibrio
cholerae colonization in vivo
We evaluated whether SIgA could alter the phenotype of V.
cholerae infection in vivo using an established model of oral
intragastric V. cholerae challenge in infant suckling mice [23].
Groups of 7-day-old infant suckling IgA
-/- and IgA
+/+ mice, either
separated (Fig 1A) or not separated from their mothers, or IgA
-/-
pups cross-fostered with lactating IgA
+/+ mothers (Fig 1B) were
challenged with V. cholerae. To evaluate the effects of innate non-
specific IgA, the bacterial burden in the small intestines was
measured at 24 hr post-challenge. As shown in Fig 1A, IgA
-/-
infant suckling mice separated from their mothers displayed
significantly (p#0.05) enhanced intestinal bacterial burden (.3
log10) when compared to the IgA
+/+ pups. Additionally, IgA
-/-
infant suckling mice not separated from their mothers displayed
significantly (p#0.05) greater intestinal bacterial burden (.2 log10)
when compared to the IgA
+/+ pups (Fig 1B), suggesting the
importance of IgA in controlling intestinal Vibrio infection.
Importantly, IgA
-/- suckling infant mice cross-fostered with
lactating IgA
+/+ mothers displayed a significant (p#0.05) reduction
(,2 log10), in intestinal bacterial burden when compared to IgA
-/-
pups with IgA
-/- dams (Fig 1B), suggesting the contribution of non-
Vibrio specific SIgA in milk to the control of intestinal V. cholerae
infection.
Non-specific human SIgA inhibits biofilm formation by
Vibrio cholerae
Based on in vivo evidence in the infant mouse model that non-
specific SIgA contributes to the reduction of virulence and/or
colonization of V. cholerae, and that biofilm formation is associated
with virulence of this bacterium [24], we further investigated the
role of human non-specific SIgA on biofilm formation by V.
cholerae. Overnight cultures of V. cholerae 0139 (MO10) were diluted
to approximately 2610
6 CFU/ml in 2X LB, and 50 ml was
incubated at 30uC for 24 hr with escalating doses of human non-
specific SIgA in 50 ml PBS or PBS alone. Wells with the V. cholerae
mutant (vpsR) that is deficient in biofilm production were evaluated
as negative controls. The biofilm formation was measured as
described previously [25,26]. As shown in Fig. 2, wild type MO10
displayed significantly (p#0.05) enhanced biofilm formation
(0.4160.03) compared to vpsR (0.0460.02). The addition of SIgA
to MO10 cultures significantly (p#0.05) reducted biofilm forma-
tion across the entire examined dose range (0.06 to 2 mg/ml). At
the highest dose examined (2 mg/ml), the biofilm formation by
MO10 was comparable to that induced by vpsR, a mutant deficient
for biofilm formation. As expected, culture wells with PBS or LB
broth (no bacteria) did not display biofilm formation.
Since non-specific SIgA inhibited biofilm formation by MO10,
we evaluated whether serum immunoglobulins (IgA or IgG or
IgM) were capable of inducing similar effects using the highest
examined dose of 2 mg/ml for each immunoglobulin. As shown in
Fig 3, incubation of V. cholerae MO10 induced a high level of
biofilm formation (0.4160.02) and as expected, the V. cholerae vpsR
mutant displayed minimal biofilm (0.0460.001) formation.
Importantly, biofilm formation by V. cholerae MO10 in the
presence of SIgA (0.0760.01), but not serum IgA (0.3360.04),
IgM (0.2760.05), IgG (0.3260.04), or an unrelated antigen BSA
(0.2960.05), was significantly (p#0.05) reduced when compared to
PBS (0.4160.02). These results suggest that human non-specific
SIgA, but not serum IgA or other immunoglobulin isotypes, plays
an important role in inhibiting biofilm formation by V. cholerae.
Additionally, the effects of SIgA and serum immunoglobulins on
biofilm formation were quantified by measuring isosurface
volume. As shown in Fig 4, the isosurface volume of biofilm by
V. cholerae MO10 upon incubation with SIgA was reduced
compared to incubation with serum IgA, IgG, IgM, control BSA
or PBS alone. As expected, the vpsR mutant displayed a low
isosurface volume of biofilm. We also quantified the biofilm
Figure 1. Significance of IgA in inhibition of colonization.
Groups (n=5–7) of seven-day old infant suckling BL6/129 (IgA
+/+) and
IgA
-/- pups were challenged intra-gastrically through the oral route with
10
6 CFU of MO10. The mice were either (A) separated from the nursing
dams or (B) housed with the nursing dams of the same strain, or IgA
-/-
pups were fostered with IgA
+/+ nursing dams. At 24 hr after challenge,
small intestines were removed, homogenized, and the bacterial
burdens analyzed. Each marker represents an individual pup and the
mean6SD also is shown. * Significant difference in numbers of bacteria
observed between the indicated groups (p#0.05, Student’s t test).
Results are representative of two to three independent experiments.
doi:10.1371/journal.pone.0016847.g001
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the qualitative results. As shown in Fig. 4B, MO10 grown with
added PBS displayed a high isosurface volume (17236353 mm
3)o f
biofilm, which was comparable to that induced in wells that
included BSA (16326403 mm
3), serum IgA (21336261 mm
3), or
IgG (2455643 mm
3). However, the isosurface volume of biofilm
was significantly (p#0.05) reduced in wells containing MO10
incubated in the presence of SIgA (728642 mm
3), or in wells of the
biofilm mutant vpsR (690635 mm
3). In fact, the addition of SIgA
to MO10 reduced the biofilm isosurface volume to levels
comparable to that of the biofilm deficient vpsR.
We further determined whether the reduction in biofilm
formation of MO10 was due to bacteristatic or bactericidal effects
induced by SIgA. Cultures of MO10 were grown for 24 hr in the
presence of SIgA, serum IgA, serum IgG, or BSA. None of the
immunoglobulins, including SIgA, displayed any significant
change in growth characteristics of MO10 when compared to
BSA (data not shown). Collectively, these results demonstrate the
efficacy of non-specific SIgA in inhibiting the biofilm formation
without affecting viability of Vibrio cholerae.
Mannose containing oligosaccharides of non-specific
human SIgA mediate inhibition of MO10 biofilm
formation
Since SIgA, but not other serum immunoglobulins, inhibited
biofilm formation by MO10, we hypothesized that the high
oligosaccharide content in the secretory component of SIgA [27]
may be responsible for the observed effects. To address this
possibility, SIgA was treated with the enzyme EndoH to cleave the
chitobiose core and release the high mannose terminal sugar
residues. As shown in Fig. 5, EndoH-treated SIgA displays a
reduced molecular weight of the SC and IgA heavy chain when
compared to untreated SIgA, suggesting removal of oligosacca-
harides. Since the change in the molecular weight of SIgA was
low, we also incubated EndoH with a positive RNaseB control and
found clear reduction in the molecular weight of RNaseB,
suggesting the efficient glycosidase activity of EndoH. Addition-
ally, human non-specific SIgA (200 mg) was incubated with
EndoH (25,000 units) in sodium citrate buffer (G5 buffer) at
37uC for 4 hr. The remaining EndoH was removed by filtration
and the EndoH-treated SIgA was incubated with overnight V.
cholerae culture, diluted to 2610
6 CFU/ml, in equal amounts at
30uC without shaking. Untreated SIgA in buffer and buffer alone
were used as positive and negative controls, respectively, for
inhibition of biofilm formation by MO10. As shown in Fig 6,
MO10 expectedly produced significantly (p#0.05) greater biofilm
formation (1.6260.25) compared to vpsR (0.2460.1). The
addition of untreated SIgA (0.5760.076), but not EndoH-treated
SIgA (1.260.1), induced a significant (p#0.05) reduction in biofilm
formation by MO10. To confirm our hypothesis further, we
evaluated whether addition of free mannose could inhibit biofilm
formation by MO10. Cultures of MO10 were compared for
biofilm formation with addition of increasing concentrations
(0.0125% to 0.1%) of free mannose in PBS. As shown in Fig 7,
mannose significantly (p#0.05) inhibited biofilm formation by
MO10 in a dose dependent fashion (0.2260.01 at 0.03%;
0.2860.01 at 0.015%, 0.3160.02 at 0.007%; 0.4360.04 at
0.0035%) when compared to cultures with PBS added alone
(0.960.06), and the inhibitory effect of mannose was lost with very
low doses of mannose (1.160.1 at 0.0015%). Together, these
results suggest that the terminal high-mannose residues on the
SIgA contribute significantly to the inhibition of biofilm formation
by V. cholerae.
Discussion
Secretory IgA is the principal immunoglobulin at mucosal sites
and plays an important role in extracellular/intracellular neutral-
ization and immune exclusion, functions that maintain mucosal
homeostasis [12]. While the role of antigen-specific SIgA has been
well studied in various models of infectious disease [11], the
contribution and function of non-specific SIgA in modulating
innate defenses is underappreciated. In this study, we demonstrate
that non specific SIgA plays an important role in control of
intestinal Vibrio cholerae infection. Moreover, non-specific human
Figure 2. Dose dependant effect of non-specific human SIgA
on MO10 biofilm formation. Overnight cultures of MO10 were
diluted and incubated without shaking for 24 hr at 30u C with
escalating doses of human non-specific SIgA. MO10 without SIgA and
the biofilm mutant vpsR were evaluated as positive and negative
controls, respectively. Biofilm formatin was measured using crystal
violet staining. Significant (p#0.05, Student’s t test) difference in biofilm
formation between * indicated group and PBS, and indicated group
and vpsR. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0016847.g002
Figure 3. Influence of non-specific SIgA and serum human
immunoglobulins on MO10 biofilm formation. Overnight cul-
tures of MO10 were diluted and incubated without shaking for 24 hr at
30u C with 2 mg/ml doses of human non-specific SIgA or serum IgA,
IgG, IgM, or BSA. MO10 without immunoglobulin and the biofilm
mutant vpsR were evaluated as positive and negative controls,
respectively. Significant (p#0.05, ANOVA) difference in biofilm forma-
tion between * indicated group and PBS. Results are representative of
three independent experiments.
doi:10.1371/journal.pone.0016847.g003
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biofilm formation by V. cholerae, in a process that was mediated by
the high mannose containing oligosaccharides of SIgA.
Antigen-specific immune responses including Ag-specific SIgA
have been shown to be involved in protection against pathogens.
In general, SIgA has been shown to neutralize pathogen infectivity
in the mucosal lumen, during transcytosis in intraepithelial cell
compartments, and in the lamina propria [8–10]. Specifically with
regard to V. cholerae, Guentzel et al. [28] demonstrated that the
anti-flagellar sheath SIgA and SIgA directed against naked flagella
or outer membrane microvesicles from non-flagellated organisms
reduced the virulence of the pathogen in the suckling infant mouse
model [29]. Since motility was associated with virulence of V.
cholerae in the infant mouse model [30], a suggested mechanism
was that the organisms were prevented from traversing the mucus
layer thus gaining access through intervillous spaces down to the
intestinal crypts; these relatively ‘‘unstirred’’ regions were observed
to be a primary niche of the bacterium during infection [28,31].
Recent reports also support these observations by demonstrating
that mucosal immunization with outer membrane vesicles induced
anti-V. cholerae LPS antibodies that inhibit bacterial motility and
reduce the virulence of V. cholerae in the infant suckling mouse
model [32]. There was a minimal role for bacterial killing and/or
anti-cholera toxin antibodies in these observed effects in both the
early and recent studies. Collectively, antigen-specific SIgA clearly
plays a role in defense against V. cholerae.
In this study, we focused on the contribution of non antigen-
specific SIgA against V. cholerae infections. A role for the free
secretory component (SC) has been suggested in innate immunity
against various pathogens including enterotoxigenic [33] and
Figure 4. Quantification of inhibiton of MO10 biofilm formation by non-specific human SIgA. Overnight cultures of GFP-expressing
MO10 were diluted and incubated without shaking for 24 hr at 30u C with a 2 mg/ml dose of human non-specific SIgA or serum IgA, IgG, IgM, or with
BSA. MO10 without immunoglobulin and the GFP expressing biofilm mutant vpsR were evaluated as positive and negative controls, respectively. (A)
Three dimensional images were obtained using a Zeiss Axiovert 200M microscope equipped with an apotome. (B) The respective isosurface volumes
were quantified using Imaris software. Significant (p#0.05, ANOVA) difference in biofilm formation between * indicated group and V. cholerae grown
in the presence of serum IgG or serum IgA. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0016847.g004
Figure 5. Digestion of SIgA with EndoH. 2 mg/ml of SIgA alone (lane 1) or SIgA with EndoH in buffer (lane 2), RNaseB alone (lane 3) or RNaseB
with EndoH (lane 4) were incubated for 4 hr at 37uC, and then subjected to SDS-PAGE and stained with Coomassie blue. Results are representative of
three independent experiments.
doi:10.1371/journal.pone.0016847.g005
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for the SC of SIgA in the observed effects. Specifically, these
studies employed in vitro model systems and demonstrated a dose
dependent effect of milk components including free SC on
pathogen-binding and/or blocking pathogen infectivity. It also
was shown that glycans in free SC are responsible for binding and
reducing the infectivity of enteropathogenic E. coli and the
cytopathic affect of Clostridium difficile toxin A [35]. We extend
these observations by demonstrating that SC-containing SIgA, but
not non-SC containing immunoglobulins including serum IgA,
IgG and IgM, are capable of inhibiting biofilm formation by the
MO10 strain of V. cholerae. This suggested that the SC itself of SIgA
may be responsible for the biofilm inhibitory effects. This effect of
SIgA was dose dependent and was observed even at 0.06 mg/ml,
a concentration below the physiological levels present in mucosal
secretions. The biofilm inhibitory effect of SIgA was dependent
upon the oligosaccharides, since cleaving the chitobiose core
reversed the effect. Additionally, the terminal residues of the
oligosaccharide side chains contain high-mannose residues, and
the addition of free mannose inhibited biofilm formation by
MO10, collectively suggesting that the terminal high mannose
residues in oligosaccharides in SIgA may be predominantly
responsible for inhibition of biofilm formation by Vibrio cholerae.
It is to be noted that the biofilm inhibitory properties of SIgA
did not involve bacterial killing. Similar results were reported
recently by Bishop et al. [32] that the anti-V. cholerae LPS antibody
reduces bacterial motility and infectious burden independent of
bacterial killing. Additionally, Guentzel et al [28] demonstrated
that treatment with anti-IgA reversed the immobilization of motile
vibrios allowing them to breach the mucus barrier and spread
along the villi, and was associated with reversal of protection in
animals immunized with flagellar or vesicular vaccines. The
reduction of infectious burden without an effort to eliminate the
pathogen appears to align well with the hypothesis that mucosal
immunoglobulins protect without eliciting much inflammation
[36], given the expected serious consequences of strong inflam-
matory responses at mucosal surfaces. This also is supported by the
finding that IgA, as opposed to the predominant serum
immunoglobulin IgG or IgM, does not activate the classical
complement pathway, and is at best a weak inducer of the
alternative complement pathway [37,38]. Thus, it appears that the
mucosal immunoglobulin IgA evolved to meet the tailored needs
for protection of mucosal surfaces [36]. To this end, it has been
demonstrated recently that most, if not all, jawed vertebrate taxa
display a functionally similar but specific mucosal immunoglobulin
isotype IgA (mammals and birds), IgX (amphibians), or IgT (bony
fish) [39]. IgA, IgX, and IgT have been suggested to be products of
convergent evolution, implying the recruitment of a unique
immunoglobulin to mucosal immunity at least three times [39].
Collectively, these results emphasize the unique nature of SIgA
when compared to other immunoglobulins in host defenses against
pathogens.
Biofilm formation has been suggested to be an important aspect
of virulence in V. cholerae [17]. Specifically, removal of V. cholerae
biofilm-like aggregates from cholera stools reduces the infectivity
significantly [21]. Therefore, SIgA and/or free SC may act as host
defense mechanisms to curtail the formation of such biofilm-like
aggregates in vivo and reduce the virulence of V. cholerae, an idea
clearly supported by the results from our in vivo experiments. IgA
-/-
infant suckling mice displayed significantly enhanced intestinal V.
cholerae burden as early as 24 hr post challenge compared to IgA
+/+
pups, suggesting a role for innate, non antigen-specific, mecha-
nisms in the protective effect, as also has been shown previously
[40]. In fact, this study by Hsiao et al., 2006 also demonstrated that
the mannose sensitive hemagglutinin (mshA) of V. cholerae is
important for binding to SIgA, and that this mannose sensitive
interaction prevents the bacterium from penetrating mucus
barriers and attaching to epithelial cells. The results of the current
study confirm and extend these observations by demonstrating
that intestinal colonization by V. cholerae and in vitro biofilm
formation are reduced upon interaction with SIgA in a mannose
dependent fashion. Such protective effects of IgA were apparent
both in IgA
+/+ pups separated from the IgA
+/+ dams, or if the
dams were allowed to nurse the pups. Importantly, the reduction
in bacterial burdens with the cross-fostering of IgA
-/- pups with
IgA
+/+ mothers suggests that passive transfer of IgA in milk
contributed to the protective effect. In mucosal secretions
including milk, IgA is secreted as dimeric SIgA, thus suggesting
that non-specific SIgA contributes to the reduction in V. cholerae
burden in the intestines. Additionally, the enhancement of
Figure 6. Inhibition of MO10 biofilm formation through high
mannose residues on oligosaccharide side chains of non-
specific human SIgA. Overnight cultures of MO10 were diluted and
grown with 2 mg/ml of SIgA, or SIgA treated with EndoH, or without
immunoglobulin for 24 hr at 30uC. Biofilm formation was quantified as
before using crystal violet stain. Significant (p#0.05, ANOVA) difference
in biofilm formation between * indicated group and MO10 without
SIgA. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0016847.g006
Figure 7. Inhibition of MO10 biofilm formation by free
mannose. Overnight cultures of MO10 were diluted and grown with
progressively reducing doses of mannose, or without mannose (PBS) for
24 hr at 30uC. Biofilm formation was quantified as before using crystal
violet stain. Significant (p#0.05, ANOVA) difference in biofilm formation
between * indicated group and MO10 without mannose. Results are
representative of three independent experiments.
doi:10.1371/journal.pone.0016847.g007
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-/- suckling infant mice occurred
despite the presence of an intact polymeric immunoglobulin
receptor (pIgR), and therefore presumably normal levels of free
SC, suggesting that the SIgA containing SC plays a predominant
role in innate protective immunity against V. cholerae in vivo. This is
supported by reports that differences in oligosaccharide compo-
sition between serum IgA and SIgA may also result from
differences in IgA1 and IgA2 composition, which differ substan-
tially in oligosaccharide content [5]. Specifically, serum IgA is
primarily composed of IgA1, whereas SIgA is an approximately
equal mixture of IgA1 and IgA2, and IgA2 contains greater
oligosaccharides than IgA1 [5]. However, a role for SC is
supported by other studies which show that the SC in human milk
binds to Clostridium difficile toxin A receptors [41], and thus may
inhibit toxin-mediated disease, suggesting that differences in
oligosaccharide composition within IgA subclasses itself, or due
to the presence of SC may contribute to protection against
mucosal pathogens. The implications of such effects may be
manifold including, but not limited to, (a) reduction in intestinal
pathogenic burden, (b) reduced concentrations of toxins in the gut
microenvironment, and/or (c) reduced systemic spread of the
pathogen, all subsequently resulting in reduced disease manifes-
tation.
In summary, this study demonstrates that high mannose
containing oligosaccharides of SIgA play an important role in
reducing the intestinal burden of Vibrio cholerae. Beyond the well
characterized adaptive immune defenses by antibodies, these
results suggest the involvement of mucosal immunoglobulins in
innate host defenses against mucosal pathogens in general. Given
that primary IgA deficiency affects approximately 1 in 500 people
[42], the results of this study underscore the need to further
evaluate in detail the nature of the predisposition of these
individuals to gut pathogens.
Materials and Methods
Ethics Statement
All animal experiments were performed in compliance with the
Animal Welfare Act, the U.S. Public Health Service Policy on
Humane Care and Use of Laboratory Animals and the ‘‘Guide for
the Care and Use of Laboratory Animals’’ published by the
National Research Council. The University of Texas at San
Antonio Institutional Animal Care and Use Committee (IACUC)
approved this study under the protocol number MU013-08/11A0.
Bacterial strains
A virulent Vibrio cholerae O139 strain, MO10 [22], was used for
this study and a defined mutant of MO10 flaA::Cm _vpsR _lacZ
designated vpsR [26], defective in biofilm formation, was used as a
control for the experiments. For isosurface volume quantification,
green fluorescent protein (GFP) expressing strains of MO10 and
vpsR were utilized.
Infant mouse colonization assays
Mice were housed and bred at the University of Texas at San
Antonio and provided food and water ad libitum.A n i m a lc a r ea n d
experimental procedures were performed in compliance with the
Institutional Animal Care and Use Committee (IACUC)
guidelines. Groups (n=5-7) of 7-day old IgA
+/+ (BL6/129) and
IgA
-/- mice [43] were challenged through the oral route
intragastrically with 10
6 CFU of MO10 in sterile saline using
intramedic tubing. In one experiment, pups were separated from
the mothers in the group. In the other, the pups were allowed to
remain in the cage with nursing dams. Additionally, one group of
IgA
-/- pups were fostered with IgA
+/+ nursing dams as a source of
breast milk SIgA. Approximately 24 hrs later, pups were
euthanized and the entire small intestine was removed. Small
intestines were homogenized and serial dilutions plated on LB
agar containing 50 mg/ml streptomycin (Sigma Aldrich, St.
Louis, MO) and incubated for 24 hr at 37uC for determination
of Vibrio cholerae burdens.
Biofilm formation
A micotiter plate assay was adapted for the evaluation of biofilm
formation. Briefly, V. cholerae 0139 (MO10) and the vspR mutant
were grown overnight at 37u C with shaking in LB containing
50 mg/ml streptomycin. The bacterial cultures were diluted in 2X
LB to a concentration of approximately 2610
6 CFU/ml and
50 mL was inoculated into sterile 96-well polystyrene microtiter
plates along with 50 mL of PBS, or bovine serum albumin (BSA)
(Fisher Scientific, Fairlawn, NJ) or serum immunoglobulin A (IgA,
Pierce, Rockford, IL) or secretory IgA (SIgA) (Sigma Aldrich) or
human serum IgG (Pierce) or human serum IgM (Pierce) at a final
concentration of 200 mg/well in PBS. In another experiment,
escalating doses of free mannose (Difco, Detroit, MI) (serially
doubling from 0.0015% to 0.03%) were added to cultures of
MO10. Cultures were incubated without shaking for 24 hr at 30u
C, removed, and the plates washed 3X with PBS and allowed to
dry. Biofilms were quantified using crystal violet staining for
15 min as described previously [25;26], washed with 1X PBS, and
the absorbance was measured at 570 nm using a mQuant ELISA
plate reader (BioTek, Winooski, VT).
Three-dimensional imaging
MO10 was grown overnight at 37u C in LB containing
50 mg/ml streptomycin. Overnight cultures were diluted to a
final concentration of approximately 2610
6 CFU/ml using
f r e s hL Bw i t hs t r e p t o m y cin and kanamycin and 150 mLo ft h i s
suspension was inoculated into sterile 24-well polystyrene
microtiter plates containing cover slips. Proteins were added
to the wells containing MO10 at a concentration of 2 mg/ml in
a total volume of 150 mLa n dt h ec u l t u r e sw e r ea l l o w e dt o
incubate for 24 hr at 30u C without shaking. One set of
triplicate wells containing the vpsR mutant, defective for biofilm
formation, was evaluated as a negative control. After incuba-
tion, the cover slips were removed and washed with sterile 1X
PBS, and mounted on glass slides with FluorSave Reagent
(Calbiochem, La Jolla, CA). Slides were imaged using a Zeiss
Axiovert 200M (Carl Zeiss Vision Microimaging Inc., Thorn-
wood, NY) microscope equipped with an apotome and analysis
of volume was performed using Imaris software (Bitplane Inc.,
Saint Paul, MN).
High mannose digestion assay and biofilm formation
High mannose sugars on SIgA were enzymatically removed
using Endoglycosidase H (Endo H, New England Biolabs, MA)
digestion. Briefly, 200 mg of SIgA was incubated in the presence of
EndoH (25,000 units) and G5 buffer at 37u C for 4 hr. A positive
RNaseB control provided by the manufacturer also was used to
evaluate the glycosidase activity of EndoH. Following the 4 hr
incubation period, sample mixtures were subjected to SDS-PAGE
electrophoresis to confirm the glycosidase activity of EndoH.
Following EndoH treatment, SIgA also was loaded on a
Microcentricon (MilliPore, MA) of 100 kDa cutoff to separate
the cleaved sugars. The treated SIgA was resuspended in 50 mLo f
sterile PBS and incubated with MO10 for biofilm formation as
described earlier.
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SigmaStat (Systat Software Inc., San Jose, CA) was used to
perform tests of significance. The Student’s t test was used to
compare two groups. For comparison between multiple groups,
one-way analysis of variance (ANOVA) was used. All experiments
were repeated and analyzed independently.
Author Contributions
Conceived and designed the experiments: AKM MNG JPC KEK BPA.
Performed the experiments: BRC TT MNG JY. Analyzed the data: AKM
BRC TT MNG JPC BPA. Contributed reagents/materials/analysis tools:
JPC KEK SKA CML. Wrote the paper: AKM BRC MNG BPA.
References
1. Brandtzaeg P (2009) Mucosal immunity: induction, dissemination, and effector
functions. Scand J Immunol 70: 505–515.
2. van der Heijden PJ, Stok W, Bianchi AT (1987) Contribution of immunoglob-
ulin-secreting cells in the murine small intestine to the total ‘background’
immunoglobulin production. Immunology 62: 551–555.
3. Kaetzel CS (2001) Polymeric Ig receptor: defender of the fort or Trojan horse?
Curr Biol 11: R35–R38.
4. Mestecky J, McGhee JR (1987) Immunoglobulin A (IgA): molecular and cellular
interactions involved in IgA biosynthesis and immune response. Adv Immunol
40: 153–245.
5. Kerr MA (1990) The structure and function of human IgA. Biochem J 271:
285–296.
6. Cunningham-Rundles C (2001) Physiology of IgA and IgA deficiency. J Clin
Immunol 21: 303–309.
7. Woof JM, Kerr MA (2006) The function of immunoglobulin A in immunity.
J Pathol 208: 270–282.
8. Lamm ME, Robinson JK, Kaetzel CS (1992) Transport of IgA immune
complexes across epithelial membranes: new concepts in mucosal immunity.
Adv Exp Med Biol 327: 91–94.
9. Mestecky J, Russell MW, Elson CO (1999) Intestinal IgA: novel views on its
function in the defence of the largest mucosal surface. Gut 44: 2–5.
10. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG (1992)
Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl
Acad Sci USA 89: 6901–6905.
11. Lamm ME (1997) Interaction of antigens and antibodies at mucosal surfaces.
Annu Rev Microbiol 51: 311–340.
12. Mason KL, Huffnagle GB, Noverr MC, Kao JY (2008) Overview of gut
immunology. Adv Exp Med Biol 635: 1–14.
13. Murthy AK, Dubose CN, Banas J, Coalson JJ, Arulanandam BP (2006)
Contribution of polymeric immunoglobulin receptor to regulation of intestinal
inflammation in dextran sulfate sodium-induced colitis. J Gastroenterol Hepatol
21: 1372–1380.
14. Corthesy B (2010) Role of secretory immunoglobulin A and secretory
component in the protection of mucosal surfaces. Future Microbiol 5: 817–829.
15. Royle L, Roos A, Harvey DJ, Wormald MR, van Gijlswijk-Janssen D, et al.
(2003) Secretory IgA N- and O-glycans provide a link between the innate and
adaptive immune systems. J Biol Chem 278: 20140–20153.
16. Faruque SM, Albert MJ, Mekalanos JJ (1998) Epidemiology, genetics, and
ecology of toxigenic Vibrio cholerae. Microbiol Mol Biol Rev 62: 1301–1314.
17. Donlan RM, Costerton JW (2002) Biofilms: survival mechanisms of clinically
relevant microorganisms. Clin Microbiol Rev 15: 167–193.
18. Watnick PI, Kolter R (1999) Steps in the development of a Vibrio cholerae El Tor
biofilm. Mol Microbiol 34: 586–595.
19. Yildiz FH, Schoolnik GK (1999) Vibrio cholerae O1 El Tor: identification of a gene
cluster required for the rugose colony type, exopolysaccharide production,
chlorine resistance, and biofilm formation. Proc Natl Acad Sci USA 96:
4028–4033.
20. Faruque SM, Biswas K, Udden SM, Ahmad QS, Sack DA, et al. (2006)
Transmissibility of cholera: in vivo-formed biofilms and their relationship to
infectivity and persistence in the environment. Proc Natl Acad Sci USA 103:
6350–6355.
21. Colwell RR, Huq A, Islam MS, Aziz KM, Yunus M, et al. (2003) Reduction of
cholera in Bangladeshi villages by simple filtration. Proc Natl Acad Sci USA 100:
1051–1055.
22. Waldor MK, Mekalanos JJ (1994) ToxR regulates virulence gene expression in
non-O1 strains of Vibrio cholerae that cause epidemic cholera. Infect Immun 62:
72–78.
23. Guentzel MN, Berry LJ (1974) Protection of suckling mice from experimental
cholera by maternal immunization: comparison of the efficacy of whole-cell,
ribosomal-derived, and enterotoxin immunogens. Infect Immun 10: 167–172.
24. Yildiz FH, Visick KL (2009) Vibrio biofilms: so much the same yet so different.
Trends Microbiol 17: 109–118.
25. Nesper J, Lauriano CM, Klose KE, Kapfhammer D, Kraiss A, et al. (2001)
Characterization of Vibrio cholerae O1 El tor galU and galE mutants: influence on
lipopolysaccharide structure, colonization, and biofilm formation. Infect Immun
69: 435–445.
26. Lauriano CM, Ghosh C, Correa NE, Klose KE (2004) The sodium-driven
flagellar motor controls exopolysaccharide expression in Vibrio cholerae. J Bacteriol
186: 4864–4874.
27. Tomana M, Mestecky J, Niedermeier W (1972) Studies on human secretory
immunoglobulin A. IV. Carbohydrate composition. J Immunol 108: 1631–1636.
28. Guentzel MN, Field LH, Eubanks ER, Berry LJ (1977) Use of fluorescent
antibody in studies of immunity to cholera in infant mice. Infect Immun 15:
539–548.
29. Eubanks ER, Guentzel MN, Berry LJ (1977) Evaluation of surface components
of Vibrio cholerae as protective immunogens. Infect Immun 15: 533–538.
30. Guentzel MN, Berry LJ (1975) Motility as a virulence factor for Vibrio cholerae.
Infect Immun 11: 890–897.
31. Guentzel MN, Amerine D, Guerrero D, Gay TV (1981) Association of Vibrio
cholerae mutants with the intestinal mucosa of infant mice. Scan Electron Microsc
4: 115–124.
32. Bishop AL, Schild S, Patimalla B, Klein B, Camilli A (2010) Mucosal
immunization with Vibrio cholerae outer membrane vesicles provides maternal
protection mediated by anti-lipopolysaccharide antibodies that inhibit bacterial
motility. Infect Immun 78: 4402–4420.
33. Giugliano LG, Ribeiro ST, Vainstein MH, Ulhoa CJ (1995) Free secretory
component and lactoferrin of human milk inhibit the adhesion of enterotoxi-
genic Escherichia coli. J Med Microbiol 42: 3–9.
34. Camara LM, Carbonare SB, Scaletsky IC, da Silva ML, Carneiro-Sampaio MM
(1995) Inhibition of enteropathogenic Escherichia coli (EPEC) adherence to HeLa
cells by human colostrum. Detection of specific SIgA related to EPEC outer-
membrane proteins. Adv Exp Med Biol 371A: 673–676.
35. Perrier C, Sprenger N, Corthesy B (2006) Glycans on secretory component
participate in innate protection against mucosal pathogens. J Biol Chem 281:
14280–14287.
36. Hooper LV, Macpherson AJ (2010) Immune adaptations that maintain
homeostasis with the intestinal microbiota. Nat Rev Immunol 10: 159–169.
37. Nikolova EB, Tomana M, Russell MW (1994) All forms of human IgA
antibodies bound to antigen interfere with complement (C3) fixation induced by
IgG or by antigen alone. Scand J Immunol 39: 275–280.
38. Russell MW, Reinholdt J, Kilian M (1989) Anti-inflammatory activity of human
IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated
complement activation. Eur J Immunol 19: 2243–2249.
39. Flajnik MF (2010) All GOD’s creatures got dedicated mucosal immunity. Nat
Immunol 11: 777–779.
40. Hsiao A, Liu Z, Joelsson A, Zhu J (2006) Vibrio cholerae virulence regulator-
coordinated evasion of host immunity. Proc Natl Acad Sci U S A 103:
14542–14547.
41. Dallas SD, Rolfe RD (1998) Binding of Clostridium difficile toxin A to human milk
secretory component. J Med Microbiol 47: 879–888.
42. Clark JA, Callicoat PA, Brenner NA, Bradley CA, Smith DA, Jr. (1983) Selective
IgA deficiency in blood donors. Am J Clin Pathol 80: 210–213.
43. Harriman GR, Bogue M, Rogers P, Finegold M, Pacheco S, et al. (1999)
Targeted deletion of the IgA constant region in mice leads to IgA deficiency with
alterations in expression of other Ig isotypes. J Immunol 162: 2521–2529.
Non-Specific Human sIgA Inhibits Vibrio Biofilm
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e16847